Researchers at Worcester Polytechnic Institute have developed a liquid biopsy chip that can capture signs of metastatic cancer from just a drop of blood. The device is designed to find circulating tumor cells, which are cancer cells that break away from a primary tumor and travel through the bloodstream, a key step in metastasis. Unlike many existing systems that rely on microfluidics, or the controlled movement of tiny volumes of fluid through miniature channels, this chip uses a simpler mechanical setup to help cancer cells settle and stick where they can be detected. At the bottom of each tiny test well are carbon nanotubes coated with antibodies, proteins that recognize specific markers on cancer cells. When the target cells land there, electrodes register electrical changes that signal a successful capture. The team says this approach can separate cancer cells from the many ordinary cells and particles in blood more effectively than some current methods. It may also trap exosomes, the nanoscale packets released by cells that can carry clues about a tumor. Together, those features point toward a faster and potentially more practical blood test for spotting early metastasis and helping doctors choose more tailored treatments.
A different approach to liquid biopsy
Liquid biopsy has become a major goal in cancer diagnostics because it promises information about a tumor without requiring surgery or a needle biopsy from the tumor itself. Instead of removing tissue, doctors could potentially analyze blood for cancer cells, tumor DNA, or other tumor-linked material.
The challenge is that these signals are rare. A blood sample contains enormous numbers of normal blood cells, while metastatic cells may be present only in very small numbers, so any useful device has to be very good at finding the biological equivalent of a needle in a haystack.
How the WPI chip works
The WPI device is built around tiny wells containing arrays of carbon nanotubes, which are extremely small cylindrical structures made of carbon. These nanotubes are coated with antibodies chosen to bind to markers on the surface of cancer cells.
Rather than pushing cells past these capture points in flowing liquid, the chip lets them settle downward through the sample. That matters because the target cells have a chance to come into direct contact with the antibody-coated surface, increasing the odds that they will be caught and identified.
Why settling may beat flow
Many liquid biopsy chips use microfluidic channels, where cells move in a stream and must bind to anchored antibodies while in motion. That design can work, but it gives cells only a brief opportunity to attach, and not every target cell will collide with the right spot at the right time.
WPI's approach uses differential settling, meaning particles and cells separate partly based on how they sink through the fluid. This helps isolate cancer-related material from the rest of the blood before detection, and the researchers report that it improves capture efficiency compared with microfluidic systems.
What the sensors detect
The chip does more than just physically trap cells. It also includes electrodes that detect electrical changes when captured cancer cells bind at the test site, creating a measurable signal instead of relying only on visual inspection under a microscope.
That combination of capture and sensing could make the platform more useful in routine testing. A chip that both isolates rare cells and reads them out electronically is a step toward a lab tool that is faster, more standardized, and easier to scale.
Beyond cells: exosomes add another clue
One especially interesting feature is that the chip may also capture exosomes. These are tiny membrane-bound packages released by cells, including cancer cells, and they carry proteins and genetic material that can reveal what is happening inside a tumor.
Exosomes matter because they may appear even when intact circulating tumor cells are scarce. If one test can gather both whole metastatic cells and tumor-derived exosomes, it could give clinicians a broader snapshot of disease activity from the same small blood sample.
Why This Matters
Metastasis is what makes many cancers deadly, because once cancer spreads to distant organs it becomes much harder to treat. A simple blood test that detects metastatic activity earlier could help doctors intervene sooner, monitor whether a therapy is working, and adjust treatment before the disease advances further.
There is also a precision-medicine angle here. Because the captured cells are identified through surface markers, physicians may be able to learn more about the biology of a patient's cancer and choose therapies that better match the tumor's specific traits rather than relying only on broad treatment categories.
What comes next
The work, reported in Nanotechnology, points to a future in which liquid biopsy becomes a practical part of everyday cancer care rather than a specialized research tool. Much will depend on further validation in larger patient studies and on showing that the chip works reliably across different cancer types, but the concept is compelling: use simple physics, smart surface chemistry, and electronic sensing to pull critical cancer signals out of a drop of blood. If that promise holds up, devices like this could make metastatic detection earlier, less invasive, and far more accessible.